Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: Potential for rescue

Human Molecular Genetics

Volumn 17, Issue 20, 2008, Pages 3180-3190

  Sobolewski, Anastasia ^a   Rudarakanchana, Nung ^a   Upton, Paul D ^a   Yang, Jun ^a   Crilley, Trina K ^a   Trembath, Richard C ^b   Morrell, Nicholas W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CHAPERONE; CYSTEINE; GLYCEROL; MUTANT PROTEIN; MYC PROTEIN; SMAD1 PROTEIN; SMAD5 PROTEIN; THAPSIGARGIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GENE MUTATION; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOLOCALIZATION; IMMUNOPRECIPITATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; WILD TYPE;

AMINO ACID SUBSTITUTION; BIOLOGICAL TRANSPORT, ACTIVE; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL MEMBRANE; ENDOPLASMIC RETICULUM; GERM-LINE MUTATION; GLYCEROL; HELA CELLS; HUMANS; HYPERTENSION, PULMONARY; MODELS, BIOLOGICAL; PHENYLBUTYRATES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SMAD PROTEINS, RECEPTOR-REGULATED; THAPSIGARGIN; TRANSFECTION;

EID: 53349173222     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddn214     Document Type: Article

References (36)

1. Gaine, S.P. and Rubin, L.J. (1998) Primary pulmonary hypertension. Lancet, 352, 719-725.
2. Yi, E.S., Kim, H., Ahn, H., Strother, J., Morris, T., Masliah, E., Hansen, L.A., Park, K. and Friedman, P.J. (2000) Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am. J. Respir. Crit. Care Med., 162, 1577-1586.
3. Atkinson, C., Stewart, S., Upton, P.D., Machado, R., Thomson, J.R., Trembath, R.C. and Morrell, N.W. (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation, 105, 1672-1678.
4. Lane, K.B., Machado, R.D., Pauciulo, M.W., Thomson, J.R., Phillips, J.A., III, Loyd, J.E., Nichols, W.C. and Trembath, R.C. (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet., 26, 81-84.
5. Deng, Z., Morse, J.H., Slager, S.L., Cuervo, N., Moore, K.J., Venetos, G., Kalachikov, S., Cayanis, E., Fischer, S.G., Barst, R.J., Hodge, S.E. and Knowles, J.A. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet., 67, 737-744.
6. Yang, X., Long, L., Southwood, M., Rudarakanchana, N., Upton, P. Jeffery, T.K., Atkinson, C., Chen, H., Trembath, R.C. and Morrell, N.W. (2005) Dysfunctional Smad signalling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ. Res., 96, 1053-1063.
7. Rudarakanchana, N., Flanagan, J.A., Chen, H., Upton, P.D., Machado, R., Patel, D., Trembath, R.C. and Morrell, N.W. (2002) Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum. Mol. Genet., 11, 1517-1525.
8. Nishihara, A., Watabe, T., Imamura, T. and Miyazono, K. (2002) Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol. Biol. Cell, 13, 3055-3063.
9. Nasim, T.M., Ghouri, A., Patel, B., James, V., Rudarakanchana, N., Morrell, N.W. and Trembath, R.C. (2008) Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary hypertension. Hum. Mol. Genet., 17, 1683-1694.
10. Rosenzweig, B.L., Imamura, T., Okadome, T., Cox, G.N., Yamashita, H., ten Dijke, P., Heldin, C.H. and Miyazono, K. (1995) Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl Acad. Sci. USA, 92, 7632-7636.
11. Upton, P.D., Long, L., Trembath, R.C. and Morrell, N.W. (2008) Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells. Mol. Pharmacol., 73, 539-552.
12. Massague, J., Seoane, J. and Wotton, D. (2005) Smad transcription factors. Genes Dev., 19, 2783-2810.
13. Morello, J.P., Salahpour, A., Laperriere, A., Bernier, V., Arthus, M.F., Lonergan, M., Petaja-Repo, U., Angers, S., Morin, D., Bichet, D.G. and Bouvier, M. (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest., 105, 887-895.
14. Bernier, V., Lagace, M., Lonergan, M., Arthus, M.F., Bichet, D.G. and Bouvier, M. (2004) Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol. Endocrinol., 18, 2074-2084.
15. Robben, J.H., Sze, M., Knoers, N.V. and Deen, P.M. (2007) Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: Relevance to therapy of nephrogenic diabetes insipidus. Am. J. Physiol. Renal Physiol., 292, F253-F260.
16. Robben, J.H., Sze, M., Knoers, N.V. and Deen, P.M. (2006) Rescue of vasopressin V2 receptor mutants by chemical chaperones: Specificity and mechanism. Mol. Biol. Cell, 17, 379-386.
17. Norez, C., Antigny, F., Becq, F. and Vandebrouck, C. (2006) Maintaining low Ca2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. Traffic, 7 562-573.
18. Rubenstein, R.C., Egan, M.E. and Zeitlin, P.L. (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J. Clin. Invest., 100, 2457-2465.
19. Egan, M.E., Glockner-Pagel, J., Ambrose, C., Cahill, P.A., Pappoe, L., Balamuth, N., Cho, E., Canny, S., Wagner, C.A., Geibel, J. and Caplan, M.J. (2002) Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med., 8, 485-492.
20. Rubenstein, R.C. and Zeitlin, P.L. (1998) A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. Am. J. Respir. Crit. Care Med., 157, 484-490.
21. Zeitlin, P.L., Diener-West, M., Rubenstein, R.C., Boyle, M.P., Lee, C.K. and Brass-Ernst, L. (2002) Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol. Ther., 6, 119-126.
22. Levine, D.J. (2006) Diagnosis and management of pulmonary arterial hypertension: Implications for respiratory care. Respir. Care, 51, 368-381.
23. Gilboa, L., Nohe, A., Geissendorfer, T., Sebald, W., Henis, Y.I. and Knaus, P. (2000) Bone morphogenetic protein receptor complexes on the surface of live cells: A new oligomerization mode for serine/threonine kinase receptors. Mol. Biol. Cell, 11, 1023-1035.
24. Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R.O., Gorgun, C.Z. and Hotamisligil, G.S. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 313, 1137-1140.
25. Aridor, M. and Hannan, L.A. (2002) Traffic jams II: An update of diseases of intracellular transport. Traffic, 3, 781-790.
26. Howell, G.J., Holloway, Z.G., Cobbold, C., Monaco, A.P. and Ponnambalam, S. (2006) Cell biology of membrane trafficking in human disease. Int. Rev. Cytol., 252, 1-69.
27. Schroder, M. (2006) The unfolded protein response. Mol. Biotechnol. 34, 279-290.
28. Grubb, B.R., Gabriel, S.E., Mengos, A., Gentzsch, M., Randell, S.H., Van Heeckeren, A.M., Knowles, M.R., Drumm, M.L., Riordan, J.R. and Boucher, R.C. (2006) SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis. Am. J. Respir. Cell Mol. Biol., 34, 355-363.
29. Loo, T.W., Bartlett, M.C. and Clarke, D.M. (2004) Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein. Biochem. Biophys. Res. Commun., 325, 580-585.
30. Choo-Kang, L.R. and Zeitlin, P.L. (2001) Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am. J. Physiol. Lung Cell. Mol. Physiol. 281, L58-L68.
31. Loo, T.W., Bartlett, M.C. and Clarke, D.M. (2004) Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein. Biochem. Biophys. Res. Commun., 325, 580-585.
32. Rubenstein, R.C. and Zeitlin, P.L. (2000) Sodium 4-phenylbutyrate downregulates Hsc70: Implications for intracellular trafficking of DeltaF508-CFTR. Am. J. Physiol. Cell Physiol., 278, C259-C267.
33. Rubenstein, R.C. and Lyons, B.M. (2001) Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. Am. J. Physiol. Lung Cell. Mol. Physiol., 281, L43-L51.
34. Kubota, K., Niinuma, Y., Kaneko, M., Okuma, Y., Sugai, M., Omura, T., Uesugi, M., Uehara, T., Hosoi, T. and Nomura, Y. (2006) Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem., 97, 1259-1128.
35. Zhang, X.M., Wang, X.T., Yue, H., Leung, S.W., Thibodeau, P.H., Thomas, P.J. and Guggino, S.E. (2003) Organic solutes rescue the functional defect in delta F508 cystic fibrosis transmembrane conductance regulator. J. Biol. Chem., 278, 51232-51242.
36. Papp, E. and Csermely, P. (2006) Chemical chaperones: Mechanisms of action and potential use. Handb. Exp. Pharmacol., 405-416.